Oncologists need to monitor tumor growth during cancer treatment. AroCell has developed a test, the TK 210 ELISA for measuring the enzyme TK1, which is a protein that is elevated in the blood when there is increased cell turnover (cell growth and cell death) within the patient. A malignant tumor has high cell turnover and TK1 leaks out into the blood. A test for measuring TK1 therefore has a great potential clinical value.
AroCell
AroCell was founded in 2003. The company is located in Uppsala, Sweden and develops and commercializes tests that can be used in the prognosis, monitoring and follow-up of cancer.
